Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells

被引:65
作者
Cao, Mengde [1 ]
Cabrera, Roniel [1 ]
Xu, Yiling [1 ]
Firpi, Roberto [1 ]
Zhu, Haizhen [1 ]
Liu, Chen [1 ]
Nelson, David R. [1 ]
机构
[1] Univ Florida, Dept Med, Sect Hepatobiliary Dis, Gainesville, FL 32610 USA
关键词
hepatocellular carcinoma; PBMC; regulatory T cells; CD4(+)CD25(+) T cells; Huh7; FOXP3;
D O I
10.1038/labinvest.3700540
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Dysfunction of the host immune system in cancer patients can be due to a number of factors, including suppression of tumor-associated antigen reactive lymphocytes by CD4(+)CD25(+) regulatory T (Treg) cells. Several studies suggest that Tregs are elevated in cancer patients and that depletion of Tregs may enhance the antitumor immunity of host, but the pathogenic and mechanistic relationship between cancer and Tregs is still unclear. In this report, we show that Tregs are increased in peripheral blood mononuclear cells (PBMCs) from hepatocellular carcinoma (HCC) patients and positively correlate with tumor burden. When PBMCs are co-cultured with human hepatoma cell lines Huh7, HepG2, and Hclone5, CD4(+) CD25(+)-T cell populations increase in frequency and undergo phenotypic and functional changes. CD45RA, CD45RO, CD69, CD62L, GITR, CTLA-4, Ki67, granzyme A, granzyme B, and FOXP3 expression were upregulated in CD4(+) CD25(+) cells after in vitro exposure to HCC cell lines. CD4(+) CD25(+) T cells from PBMCs that were co-cultured with Huh7 cells also have higher suppressor ability compared to that of the CD4(+) CD25(+) T cells from control PBMC. Huh7 culture supernatants appear to promote CD4(+) CD25(+) T-cell proliferation and inhibit CD4(+) CD25(-)T-cell proliferation. In conclusion, these results strongly suggest that tumor-related factors not only induce and expand CD4(+) CD25(+) cells, but also enhance their suppressor ability.
引用
收藏
页码:582 / 590
页数:9
相关论文
共 37 条
[1]  
AWWAD M, 1989, CANCER RES, V49, P1649
[2]  
AWWAD M, 1990, CANCER RES, V50, P2228
[3]   Human CD4+CD25+ regulatory T cells [J].
Baecher-Allan, C ;
Viglietta, V ;
Hafler, DA .
SEMINARS IN IMMUNOLOGY, 2004, 16 (02) :89-97
[4]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[5]   CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity [J].
Belkaid, Y ;
Piccirillo, CA ;
Mendez, S ;
Shevach, EM ;
Sacks, DL .
NATURE, 2002, 420 (6915) :502-507
[6]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[7]   An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection [J].
Cabrera, R ;
Tu, ZK ;
Xu, YL ;
Firpi, RJ ;
Rosen, HR ;
Liu, C ;
Nelson, DR .
HEPATOLOGY, 2004, 40 (05) :1062-1071
[8]   Immunophenotypes and cytotoxic functions of lymphocytes in patients with hepatocellular carcinoma [J].
Chavan, SS ;
Chiplunkar, SV .
TUMORI, 1997, 83 (04) :762-767
[9]   IL-10 and TGF-β induce alloreactive CD4+CD25- T cells to acquire regulatory cell function [J].
Chen, ZM ;
O'Shaughnessy, MJ ;
Gramaglia, I ;
Panoskaltsis-Mortari, A ;
Murphy, WJ ;
Narula, S ;
Roncarolo, MG ;
Blazar, BR .
BLOOD, 2003, 101 (12) :5076-5083
[10]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949